G1 Therapeutics abandons PhIII colorectal cancer trial after disappointing overall response rates – Endpoints News

by

  1. G1 Therapeutics abandons PhIII colorectal cancer trial after disappointing overall response rates Endpoints News
  2. G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) Yahoo Finance
  3. GTHX stock falls on decision to halt colorectal cancer trial (NASDAQ:GTHX) Seeking Alpha
  4. Pharma Stock Hits Record Low Due to Pulled Study Schaeffers Research
  5. G1 Therapeutics to halt drug trial in colon cancer, shares plunge Reuters
  6. View Full Coverage on Google News

Read original article here

Leave a Comment